Menu
PPD Blog
PPD Blog

Sharing industry knowledge as we
help deliver life-changing therapies.

 

Infrastructure Design Is Key to Enhanced Clinical Trials Data Management thumbnail image

Infrastructure design is key to enhanced clinical trials data management

Brent Reed, director of information technology, writes about elements required for managing data for a successful clinical trial.

Read more...
 

Proactivity in a GMP Contract Laboratory thumbnail

Proactivity in a GMP contract laboratory

Chris Forsdyke, executive director, PPD® Laboratories’ GMP lab in Athlone, Ireland, details why proactivity is important even in a regulated laboratory environment.

Read more...
 

Positive changes in the Latin American clinical trial regulatory environment

Positive changes in the Latin American clinical trial regulatory environment

Andres Bayona, executive director in clinical monitoring and regional head of Latin America, and Mercedes Ponce de Leon, senior manager in regulatory affairs, discuss the clinical trial regulatory landscape in Latin America.

Read more...
 

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Jie Ding, associate director of development and validation at the PPD® Laboratories’ GMP lab, discusses liquid chromatography-mass spectrometry in drug discovery and development.

Read more...
 

First-in-health regulatory changes Kirsten Messmer

Seeking ways to ensure participant safety in first-in-human trials

Kirsten Messmer, Ph.D., R.A.C., principal regulatory affairs specialist, details changes in regulatory guidelines for first-in-human trials.

Read more...
 

Honoring World Alzheimer’s Day Neuroscience Research

Honoring World Alzheimer's Day

Stephen Peroutka, vice president and therapeutic area head in neuroscience, shares his thoughts on the importance and outlook of conducting clinical trials for Alzheimer’s disease.

Read more...
 

Brexit’s potential regulatory impact on the pharmaceutical industry

Brexit's potential regulatory impact on the pharmaceutical industry

Regulatory affairs experts at PPD, Alistair Davidson and Vincenzo Cannizzaro, reflect on how the United Kingdom's departure from the European Union might impact the pharmaceutical industry.

Read more...
 

Major clinical trial reforms underway in China’s regulatory environment thumbnail image

Major clinical trial reforms underway in China's regulatory environment

Bill Wang, director of regulatory affairs, discusses China's regulatory environment in the second-largest pharmaceutical market in the world.

Read more...
 

Pediatric research: Overcoming challenges and building community thumbnail image

Pediatric research: Overcoming challenges and building community

Horacio Plotkin, vice president and medical lead, Rare Disease and Pediatric Center of Excellence, discusses the challenges researchers face when conducting studies in the pediatric space and talks about the impact of PPD’s Pediatric Investigator Network (PIN), a network of 14 pediatric centers of excellence established to share scientific thinking, improve pediatric study design and communicate knowledge across the international research community.

Read more...
 

Charting a new course: Extractable and leachable testing thumbnail image

Charting a new course: Extractable and leachable testing

Derek Wood, an associate director for PPD® Laboratories GMP Lab, discusses the growth of extractables and leachables in the required testing for pharmaceutical products.

Read more...
Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2018 Pharmaceutical Product Development, LLC. All rights reserved.